by Kevin Dooley, MD | Mar 19, 2020 | News and Information
AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from... 
by Kevin Dooley, MD | Feb 5, 2020 | News and Information
The 2019 Million Dollar Bike Ride grant of $102,340 for inclusion body myositis (IBM) research has been awarded to Dr. Steven A. Greenberg of Brigham and Women’s Hospital and Harvard Medical School. Dr. Greenberg will study, “Development of a Chemokine Targeted... 
by Kevin Dooley, MD | Jan 29, 2020 | News and Information
A recently published study finds that the Inclusion Body Myositis Functional Rating Scale (IBMFRS) does not correlate as well as expected with measures of grip strength and finger flexor strength. This suggests that the IBMFRS could be improved to more accurately... 
by Kevin Dooley, MD | Apr 22, 2019 | News and Information
Researchers at the Yale School of Medicine in New Haven, CT are looking for patients with inclusion body myositis (IBM) to participate in a study using Electrical Impedance Myography (EIM). The purpose of the study is to learn if EIM is useful for measuring the... 
by Kevin Dooley, MD | Mar 27, 2019 | News and Information
Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually... 